Crinetics Pharmaceuticals, Inc. 4

Weston Nichols had 22,225 common shares and 114,080 stock options in Crinetics Pharmaceuticals, Inc. cashed out and canceled at the $85.00-per-share merger price in connection with the company’s acquisition by Vertex Pharmaceuticals.

On September 1, 2026, in connection with the closing of the cash merger of Crinetics Pharmaceuticals, Inc. into a subsidiary of Vertex Pharmaceuticals Incorporated at $85.00 per share, reporting person Weston Nichols had all of his equity awards and common shares canceled and cashed out. A total of 22,225 common shares (16,300 shares on one line and 5,925 shares on a second line) were converted into the $85.00 per share cash merger consideration. In addition, multiple tranches of vested stock options with varying exercise prices (ranging from $18.29 to $44.71) covering an aggregate of 114,080 shares (12,500 + 12,500 + 17,500 + 17,500 + 17,500 + 12,500 + 10,350 + 9,730) were canceled and converted into cash equal to the intrinsic value per share (the $85.00 merger price minus each option’s exercise price), resulting in cash payouts but no continuing equity interest. These transactions are characterized as disposition (“D”) events solely due to the merger, with Nichols reporting zero shares and zero options remaining beneficially owned after the Effective Time.

Filing Facts

CIK

1658247

Ticker

CRNX

Form

4

Source Type

fda

Accession

0001628280-26-059904

Alert Tier

6